Clinical Trials

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy – (some cohorts closed, check with Research Department)

A PHASE III CLINICAL TRIAL EVALUATING DEESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE ≤ 18 BREAST CANCER

A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioblastoma With Elevated Mutational Burden

The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed therapy with Venetoclax and Obinutzumab in Newly Diagnosed Asymptomatic High-Risk Patient with DLL/CLL: EVOLVE CLL/SLL Study.

(Temp Closed) Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with MM using minimal residual disease to direct therapy duration (DRAMMATIC STUDY).

(Temp Closed) Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

1ST line Metastatic Pancreatic – A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

OPENING SOON – Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) (KEYNOTE B36)

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

(CLOSED) Stage II-III Resected NSCLC – A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC

Stage II-III Resected NSCLC – Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

OPENING SOON – Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ACCIO)

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy of Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy

OPENING SOON – SGNDV-001/KN-574
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)

Phase 3 Study of MK-6482 in Combination With Lenvatinib Versus Cabozantinib for Second-line Treatment of mRCC

A Randomized Phase II trial of triplet therapy (a PD-L1 inhibitor durvalumab in combination with Olaparib and Cediranib) compared to Olaparib and Cediranib or Durvalumab and Cediranib or standard of care chemotherapy in women with Platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal or fallopian cancer who have received prior Bevacizumab

ULI-EAP-100 – Expanded Access To Ulixertinib (Bvd-523) In Patients With Advanced Mapk Pathway-Altered Malignancies

A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Cemiplimab Survivorship Epidemiology Study

A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases

Solid Tumor Matched Tissue and Blood Collection

The list of available biomarker studies is always changing. Please contact Cancer Partners Research Department for the most current list.